journal article·2024-07-24

Graphene Quantum Dots Reduce Hypertrophic Scar by Inducing Myofibroblasts To Be a Quiescent State

Hongchao Huang, Wenzhang Liu, Jiezhi Lin, Futing Shu, Zhaofan Xia, Yongjun Zheng

ACS Applied Materials & Interfaces· Volume 16· Issue 29
Publisher page

Abstract

Contrary to the initial belief that myofibroblasts are terminally differentiated cells, myofibroblasts have now been widely recognized as an activation state that is reversible. Therefore, strategies targeting myofibroblast to be a quiescent state may be an effective way for antihypertrophic scar therapy. Graphene quantum dots (GQDs), a novel zero-dimensional and carbon-based nanomaterial, have recently garnered significant interest in nanobiomedicine, owing to their excellent biocompatibility, tunable photoluminescence, and superior physiological stability. Although multiple nanoparticles have been used to alleviate hypertrophic scars, a GQD-based therapy has not been reported. Our in vivo studies showed that GQDs exhibited significant antiscar efficacy, with scar appearance improvement, collagen reduction and rearrangement, and inhibition of myofibroblast overproliferation. Further in vitro experiments revealed that GQDs inhibited α-SMA expression, collagen synthesis, and cell proliferation and migration, inducing myofibroblasts to become quiescent fibroblasts. Mechanistic studies have demonstrated that the effect of GQDs on myofibroblast proliferation blocked cell cycle progression by disrupting the cyclin-CDK-E2F axis. This study suggests that GQDs, which promote myofibroblast-to-fibroblast transition, could be a novel antiscar nanomedicine for the treatment of hypertrophic scars and other types of pathological fibrosis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Dermatologic Treatments and Research · Facial Rejuvenation and Surgery Techniques · Laser Applications in Dentistry and Medicine

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Burn Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, People’s Republic of China

Research Unit of Key Techniques for Treatment of Burns and Combined Burns and Trauma Injury, Chinese Academy of Medical Sciences, Shanghai 200433, People’s Republic of China

Funding

National Key Research and Development Program of China · Chinese Academy of Medical Sciences · National Natural Science Foundation of China · Shanghai Rising-Star Program · 173 plan project of Military Science and Technology · Changhong talent plan of Changhai Hospital · Youth Medical Talents Specialist Program · Basic medical research project of Changhai Hospital

References (54)

Show source-provided references
1. 10.1038/s41572-023-00474-x10.1038/s41572-023-00474-x ↗
2. 10.1016/S0140-6736(16)31406-410.1016/S0140-6736(16)31406-4 ↗
3. 10.1136/bmj.326.7380.8810.1136/bmj.326.7380.88 ↗
4. 10.1089/wound.2015.064610.1089/wound.2015.0646 ↗
5. 10.1371/journal.pmed.004023410.1371/journal.pmed.0040234 ↗
6. 10.1016/j.addr.2018.08.00910.1016/j.addr.2018.08.009 ↗
7. 10.1126/science.aar297110.1126/science.aar2971 ↗
8. 10.1111/j.1468-3083.2011.04200.x10.1111/j.1468-3083.2011.04200.x ↗
9. 10.1101/cshperspect.a04123110.1101/cshperspect.a041231 ↗
10. 10.1172/JCI9356310.1172/JCI93563 ↗
11. 10.1016/j.devcel.2023.04.01410.1016/j.devcel.2023.04.014 ↗
12. 10.1073/pnas.120184010910.1073/pnas.1201840109 ↗
13. 10.1016/j.msec.2020.11065110.1016/j.msec.2020.110651 ↗
14. 10.1002/adma.20190436210.1002/adma.201904362 ↗
15. 10.3390/ijms2404404610.3390/ijms24044046 ↗
16. 10.1186/s12951-022-01362-410.1186/s12951-022-01362-4 ↗
17. 10.1016/j.jep.2009.09.01410.1016/j.jep.2009.09.014 ↗
18. 10.7150/thno.5061310.7150/thno.50613 ↗
19. 10.1038/s41467-019-09929-w10.1038/s41467-019-09929-w ↗
20. 10.1016/j.jshs.2022.10.00410.1016/j.jshs.2022.10.004 ↗
21. 10.1038/s41467-021-21964-010.1038/s41467-021-21964-0 ↗
22. Darby I. · Lab. Invest. · 1990 · 63 · 21
23. 10.1038/nrm.2016.2710.1038/nrm.2016.27 ↗
24. 10.1016/j.molcel.2020.08.02010.1016/j.molcel.2020.08.020 ↗
25. 10.1002/adhm.20230056810.1002/adhm.202300568 ↗
26. 10.1126/sciadv.aaz263010.1126/sciadv.aaz2630 ↗
27. 10.1038/s41565-018-0179-y10.1038/s41565-018-0179-y ↗
28. 10.2217/nnm.15.8210.2217/nnm.15.82 ↗
29. 10.1016/j.biomaterials.2017.10.01810.1016/j.biomaterials.2017.10.018 ↗
30. 10.1016/j.abb.2019.05.01610.1016/j.abb.2019.05.016 ↗
31. 10.1021/acsnano.7b0743910.1021/acsnano.7b07439 ↗
32. 10.1016/j.drudis.2018.01.04710.1016/j.drudis.2018.01.047 ↗
33. 10.1016/j.jhazmat.2023.13175010.1016/j.jhazmat.2023.131750 ↗
34. 10.1016/j.scitotenv.2011.01.01510.1016/j.scitotenv.2011.01.015 ↗
35. 10.1002/smll.20120106910.1002/smll.201201069 ↗
36. 10.1186/s12989-022-00465-y10.1186/s12989-022-00465-y ↗
37. 10.1021/ar300028m10.1021/ar300028m ↗
38. 10.1007/s00204-012-0859-610.1007/s00204-012-0859-6 ↗
39. 10.1002/smll.20190540510.1002/smll.201905405 ↗
40. 10.1002/adhm.20130006610.1002/adhm.201300066 ↗
41. 10.1021/nn402043c10.1021/nn402043c ↗
42. 10.1016/j.biomaterials.2018.12.00110.1016/j.biomaterials.2018.12.001 ↗
43. 10.1016/j.biopha.2016.09.01010.1016/j.biopha.2016.09.010 ↗
44. 10.3390/ijms2103110510.3390/ijms21031105 ↗
45. 10.1016/j.stem.2016.10.00410.1016/j.stem.2016.10.004 ↗
46. 10.1016/S0968-0004(00)89005-210.1016/S0968-0004(00)89005-2 ↗
47. 10.1016/j.tcb.2021.05.00110.1016/j.tcb.2021.05.001 ↗
48. 10.1101/gad.6.10.187410.1101/gad.6.10.1874 ↗
49. 10.1016/j.engreg.2022.05.00210.1016/j.engreg.2022.05.002 ↗
50. 10.1016/j.bmt.2022.11.00310.1016/j.bmt.2022.11.003 ↗
51. 10.1002/SMMD.2023003410.1002/SMMD.20230034 ↗
52. 10.1007/s42765-022-00229-510.1007/s42765-022-00229-5 ↗
53. 10.1016/j.engreg.2022.06.00310.1016/j.engreg.2022.06.003 ↗
54. 10.1016/j.engreg.2022.11.00210.1016/j.engreg.2022.11.002 ↗